Article
Urology & Nephrology
K. Stinesen Kollberg, E. Holmberg, A. Josefsson, J. Hugosson, R. Arnsrud Godtman
Summary: The aim of this study was to describe the level of pre-testing and contamination in the Goteborg-1 prostate cancer screening trial. The results showed that similar proportions of men were prostate specific antigen-tested in both the screening group and control group, yet only a minority of contamination prostate specific antigens led to biopsy. Organized screening was found to be more effective in reducing prostate cancer mortality than non-organized testing.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Nathaniel F. Hansen, Joshua A. Linscott, Matthew H. Hayn, Stephen T. Ryan, Jesse D. Sammon
Summary: Immigrants in the U.S. have lower rates of PSA testing compared to non-immigrants, with Asian immigrants having the lowest rate. Citizenship status, length of residence in the U.S., and English proficiency are factors associated with increased PSA testing. Improving healthcare utilization and language services could help narrow the gap in guideline-concordant prostate cancer screening between immigrants and non-immigrants.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Jordan J. Kramer, Lin Gu, Daniel Moreira, Gerald Andriole, Ilona Csizmadi, Stephen J. Freedland
Summary: This study analyzed the association between statin use and the incidence of LUTS in asymptomatic men, as well as the progression of LUTS in symptomatic men. The results showed no significant relationship between statin use and either LUTS incidence or progression. Therefore, statins do not appear to play a role in the prevention or management of LUTS.
JOURNAL OF UROLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Ciaran N. Kohli-Lynch, James Lewsey, Kathleen A. Boyd, Dustin D. French, Neil Jordan, Andrew E. Moran, Naveed Sattar, David Preiss, Andrew H. Briggs
Summary: This study evaluates the cost-effectiveness of expanding preventive statin eligibility and novel approaches to prioritization from a Scottish health sector perspective. The findings suggest that generic pricing has made preventive statin therapy cost-effective for many adults. Additionally, an approach using absolute risk reduction (ARR)-guided therapy is more effective and cost-effective than the traditional method based on 10-year risk assessment.
Article
Urology & Nephrology
Kendrick Yim, Chaoran Ma, Sigrid Carlsson, Hans Lilja, Lorelei Mucci, Kathryn Penney, Adam S. Kibel, Scott Eggener, Mark A. Preston
Summary: Adding percent free PSA to total PSA improved prediction of clinically significant prostate cancer and fatal prostate cancer. Free PSA can be used to stratify risk in screening and reduce unnecessary prostate biopsies.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Tarik Benidir, Ethan Austhof, Ryan D. D. Ward, Justin Ream, Jenifer Bullen, Baris Turkbey, Peter A. A. Pinto, Francesco Giganti, Eric A. A. Klein, Andrei S. S. Purysko
Summary: The study aimed to evaluate the impact of UroLift on prostate magnetic resonance imaging (MRI) quality. The results showed that UroLift has a negative impact on MRI quality, particularly in the mid-basal region, obscuring a significant portion of the prostate on diffusion-weighted images.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Michael S. Leapman, Kimberly Stone, Roxanne Wadia, Lesley S. Park, Cynthia L. Gibert, Matthew B. Goetz, Roger Bedimo, Maria Rodriguez-Barradas, Fatma Shebl, Amy C. Justice, Sheldon T. Brown, Kristina Crothers, Keith M. Sigel
Summary: The risk of prostate cancer among individuals living with human immunodeficiency virus (HIV) is not well understood. This study found that when accounting for less prostate-specific antigen (PSA) testing among HIV-positive individuals, the incidence of prostate cancer was similar to that of HIV-negative individuals.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Barbara Bressi, Cinzia Iotti, Maribel Cagliari, Stefania Fugazzaro, Silvio Cavuto, Franco Antonio Mario Bergamaschi, Alfredo Moscato, Stefania Costi
Summary: The study aimed to investigate the physical exercise habits, lifestyle, and motivation to change towards healthier behaviors in newly diagnosed prostate cancer patients in Italy. The findings revealed that a majority of the participants were physically active, but did not meet the recommended exercise level. Only a small percentage of the participants were willing to change their habits. The study highlights the importance of healthcare professionals utilizing the teachable moment to support patients' motivation for exercise and adherence to healthier lifestyles.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Multidisciplinary Sciences
Libin Nan, Kai Guo, Mingmin Li, Qi Wu, Shaojun Huo
Summary: A nomogram prediction model for prostate cancer was developed using clinical data, and compared with other prediction models. The results showed that the model had higher predictive value, and could be used to assess the probability of prostate cancer and guide prostate biopsy.
Article
Urology & Nephrology
Catherine Handy Marshall, Yongmei Chen, Claire Kuo, Jennifer Cullen, Jiji Jiang, Inger Rosner, Mark Markowski, David G. McLeod, Bruce J. Trock, Mario A. Eisenberger
Summary: This study retrospectively analyzed the metastasis-free survival and overall survival of men with BCR who delayed ADT treatment. The results showed that patients who deferred treatment had longer survival times, indicating the need to reassess when to start primary ADT in this patient population.
JOURNAL OF UROLOGY
(2021)
Article
Andrology
Rimaz M. Khadir, Rashid K. Sayyid, Brian Matthews, Sherita A. King, Martha K. Terris
Summary: In patients undergoing prostate biopsy, those with a later age of first shave and taller height have an increased risk of a positive prostate biopsy and high grade prostate cancer, respectively.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2021)
Article
Urology & Nephrology
Sebastiaan Remmers, Chris H. Bangma, Rebecka A. Godtman, Sigrid. Carlsson, Anssi Auvinen, Teuvo L. J. Tammela, Louis J. Denis, Vera Nelen, Arnauld Villers, Xavier Rebillard, Maciej Kwiatkowski, Franz Recker, Stephen Wyler, Marco Zappa, Donella Puliti, Giuseppe Gorini, Alvaro Paez, Marcos Lujan, Daan Nieboer, Fritz H. Schroeder, Monique J. Roobol
Summary: Based on the guidelines of the European Association of Urology, a risk-based strategy for prostate cancer screening should be determined by the first prostate-specific antigen (PSA) level and age. In this study, the baseline PSA level was found to guide decisions on the repeat screening interval and had an impact on prostate cancer detection and specific mortality rates.
Article
Urology & Nephrology
Ivo I. de Vos, Annick Meertens, Renee Hogenhout, Sebastiaan Remmers, Monique J. Roobol
Summary: This study concludes that PSA-based screening for prostate cancer can reduce metastasis and mortality. The longer the follow-up, the greater the reduction in deaths and metastasis. The study also suggests that starting screening between the ages of 70 and 74 is not effective and repeated screenings are necessary.
Article
Urology & Nephrology
Michael S. Leapman, Rong Wang, Stacy Loeb, Tyler M. Seibert, Franklin D. Gaylis, Ben Lowentritt, Gordon A. Brown, Ronald Chen, Daniel Lin, John Witte, Matthew R. Cooperberg, William J. Catalona, Cary P. Gross, Xiaomei Ma
Summary: It is unclear whether compliance with recommended monitoring tests has changed over time for patients with localized prostate cancer undergoing observation. A retrospective cohort study of Medicare beneficiaries diagnosed with low- or intermediate-risk prostate cancer in 2004-2016 was conducted to examine rates of PSA testing, prostate biopsy, and prostate MRI. The study found that usage of recommended monitoring tests remains low among patients managed with observation and that rates of PSA testing and biopsy have increased over time. Various factors including age, clinical risk, race/ethnicity, census tract poverty, and region were associated with testing rates.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Patrick-Julien Treacy, Ugo G. Falagario, Francois Magniez, Parita Ratnani, Ethan Wajswol, Alberto Martini, Ivan Jambor, Peter Wiklund, Imad Bentellis, Flora Barthe, Natasha Kyprianou, Matthieu Durand, Daniel Steffens, Sascha Karunaratne, Scott Leslie, Ruban Thanigasalam, Ash Tewari
Summary: This study aimed to evaluate the genomic risk of patients with persistent prostate specific antigen (PSA) using mRNA expression analysis and a validated prognostic genomic-risk classifier. The findings revealed unique genomic features of patients with persistent PSA and confirmed that this condition is associated with a worse prognosis.
MINERVA UROLOGY AND NEPHROLOGY
(2023)
Article
Oncology
Ronald de Wit, Stephen J. Freedland, Stephane Oudard, Georgi Marinov, Philippe Capart, Austin J. Combest, Ryan Peterson, Ayse Ozatilgan, Alicia K. Morgans
Summary: This study compared the characteristics and treatment patterns of real-world prostate cancer patients with those of the population in the CARD study, and found that the treatment responses were similar in both populations.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
John M. Masterson, Michael Luu, Aurash Naser-Tavakolian, Stephen J. Freedland, Howard Sandler, Zachary S. Zumsteg, Timothy J. Daskivich
Summary: The number and density of metastatic lymph nodes on lymphadenectomy predict mortality in prostate cancer. The study found that the impact of lymph node density on overall mortality is negligible in patients with 3 or fewer metastatic lymph nodes, who make up the majority of patients with metastatic lymph nodes. Pathological nodal staging should primarily focus on the count of lymph nodes rather than density.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Editorial Material
Oncology
Gloria Cecilia Galvan, James P. Daniels, Nadine A. Friedrich, Sanjay Das, Stephen J. Freedland
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Letter
Medicine, General & Internal
Farnoosh Nik-Ahd, Amanda De Hoedt, Christi Butler, Jennifer T. Anger, Peter R. Carroll, Matthew R. Cooperberg, Stephen J. Freedland
Summary: This case series examined the frequency of prostate cancer diagnoses in transgender women receiving care at the Veterans Affairs health system.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Urology & Nephrology
Farnoosh Nik-Ahd, Justin Waller, Amanda M. DeHoedt, Maurice M. Garcia, Jane C. Figueiredo, Peter R. Carroll, Matthew R. Cooperberg, Stephen J. Freedland
Summary: The study aimed to explore the sensitivity and specificity of five commonly used ICD codes in identifying transgender patients, specifically transgender women, using data from the Veterans Affairs. The results showed that these ICD codes are highly sensitive in identifying transgender patients, and the combination with orchiectomy is extremely sensitive in identifying transgender women.
JOURNAL OF SEXUAL MEDICINE
(2023)
Editorial Material
Urology & Nephrology
Sanjay Das, Jun Gong, Stephen J. Freedland
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Paige K. Kuhlmann, Taofik Oyekunle, Zachary Klaassen, Christopher L. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Martha K. Terris, Stephen J. Freedland
Summary: This study aimed to provide data support for the choice between active surveillance (AS) and treatment for men with favorable intermediate risk (FIR) prostate cancer. By retrospectively reviewing data from a cohort of men undergoing radical prostatectomy (RP), the theoretical risk of prostate cancer-specific mortality (PCSM) with AS was estimated and compared to RP. The results showed that even with a 1.25x to 2x increased risk of PCSM compared to RP, the risk of death for FIR men choosing AS is still low, up to 15 years.
Article
Biochemical Research Methods
Celina H. Shirazipour, Rachel M. Ruggieri-Bacani, Laura Lockshon, Christopher Waring, Aubrey Jarman, Novalyn Cruz, Catherine Bresee, Angela J. Fong, Pao-Hwa Lin, Gillian Gresham, Arash Asher, Stephen J. Freedland
Summary: This study aims to investigate the feasibility of personalized Zoom-delivered exercise training for breast and prostate cancer survivors, as well as the preliminary efficacy of participation on various health indicators. A 24-week feasibility study will be conducted, involving virtual personal training via Zoom and follow-up exercise using recorded sessions. Physical assessments and surveys will be conducted at multiple time points. Further research is needed to understand the feasibility and effectiveness of virtual exercise programming.
METHODS AND PROTOCOLS
(2023)
Article
Medicine, Research & Experimental
Stephen J. J. Freedland, Matthew R. R. Davis, Andrew J. J. Epstein, Bhakti Arondekar, Jasmina I. I. Ivanova
Summary: This study analyzed healthcare resource utilization (HRU) and healthcare costs in men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population. The findings showed a substantial increase in HRU and healthcare costs following mCRPC diagnosis, particularly in outpatient care and physician visits. These results help to quantify the economic burden of mCRPC and the value of treatments that delay disease progression.
ADVANCES IN THERAPY
(2023)
Article
Oncology
Xudong Ni, Michael Luu, Weiwei Ma, Tingwei Zhang, Yu Wei, Stephen J. Freedland, Dingwei Ye, Timothy J. Daskivich, Yao Zhu
Summary: Asian males with de novo metastatic prostate cancer have better overall survival and cancer-specific survival compared to white males across different treatment regimens.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2023)
Article
Oncology
Sanjay Das, Nadine A. Friedrich, James Daniels, G. Cecilia Galvan, Jun Gong, Edwin Posadas, William Aronson, Stephen J. Freedland
Summary: This study compares public interest in FDA-approved drugs for advanced prostate cancer and finds that Bicalutamide remains relatively popular, especially among lower-income individuals, those without health insurance, and in states that did not expand Medicaid.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Meeting Abstract
Oncology
Nischal Mahaveer Chand, Poornima K. Tekumalla, Albert Dobi, Amina Ali, Gregory M. Miller, Juan J. Aristizabal-Henao, Elder Granger, Stephen J. Freedland, Shiv Srivastava, Jose Arturo Rodriguez Rivera, Arturo Mendoza, David G. McLeod, Niven R. Narain, Michael A. Kiebish
Meeting Abstract
Oncology
Julie A. Barta, Stephen Freedland, Peter J. Mazzone, Amy E. Isaacson, Alisa M. Hewitt, Debbie Jakubowski, Peter B. Bach, Victor E. Velculescu
Review
Urology & Nephrology
Jun Gong, Daniel M. Kim, Michael R. Freeman, Hyung Kim, Leigh Ellis, Bethany Smith, Dan Theodorescu, Edwin Posadas, Robert Figlin, Neil Bhowmick, Stephen J. Freedland
Summary: Black men with prostate cancer have biologically distinct cancers compared to white men, including genetic alterations, protein differences, and tumor microenvironment. Socioeconomic status partially explains the disparities, but not completely. Further research on these biological differences can guide efforts to improve treatment outcomes for Black men.
NATURE REVIEWS UROLOGY
(2023)
Article
Urology & Nephrology
Stephen J. Freedland, Sandhya Nair, Xiwu Lin, Lawrence Karsh, Christopher Pieczonka, Ravi Potluri, Sabine D. Brookman-May, Suneel D. Mundle, Sarah Fleming, Neeraj Agarwal
Summary: This study evaluated patient characteristics, treatment patterns, and outcomes in men with localized or locally advanced prostate cancer using real-world data.
WORLD JOURNAL OF UROLOGY
(2023)